Business
Update on the Virtual Tumour Clinical platform
Update on the Virtual Tumour Clinical platform.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 0050S Physiomics PLC 04 November 2013 \n \n\nPhysiomics plc\n(\"Physiomics\") or (\"the Company\")\n \nPhysiomics to update on the Virtual Tumour Clinical platform at the 2013 NCRI Cancer Conference \n \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 NCRI Cancer Conference, taking place at the BT Convention Centre, Liverpool, on 3-6 November 2013. Dr Eric Fernandez, Project Leader, will present details of the on-going development of the Virtual Tumour Clinical platform.\n \nThe results presented show that Virtual Tumour Clinical correctly ranked different clinical regimens from the literature. In this case study varying the timing of administration of EGFR inhibitors in combination with chemotherapy led to improved efficacy.\n \nThe abstract (\"Dosing and schedule optimization with Virtual Tumour Clinical \") No B60 will be presented in the \"Diagnosis and therapy\" poster session B scheduled Tuesday the 5th of November April 2013.\n \nMore information about the conference may be found at:\nhttp://conference.ncri.org.uk/ \n \nDr Mark Chadwick, CEO of Physiomics, commented:\n\"We are pleased to present the advances that we have made developing our flagship Virtual Tumour Clinical platform for the first time at the NCRI conference. Under our technology strategy board biocatalyst grant further case studies will be used to hone the accuracy of the model\"\n \n \nEnquiries:\n \nPhysiomics plc \nDr Mark Chadwick, CEO\n+44 (0)1865 784 980\n \n \nWH Ireland Limited (broker/nomad)\nKaty Mitchell\n+44 (0) 161 832 2174\n \n \n \nAbout Physiomics plc\n \nPhysiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per...